Results 71 to 80 of about 27,607 (170)

Altered Brain Tissue Volumes With Valproate Treatment for Schizophrenia

Journal of the Royal Society of New Zealand, Volume 56, Issue 2, April 2026.
Schizophrenia is a debilitating psychiatric condition that affects ≈0.5% of the global population. Some people with schizophrenia do not respond to first‐line antipsychotics and are prescribed clozapine; this is termed treatment‐resistant schizophrenia (TRS).
Thomas Cawood, Olivia K. Harrison, Meghan McIlwain, Robert R. Kydd, Bruce R. Russell   +4 more
wiley   +1 more source

Olanzapine-induced Pancytopenia: Case Report

Medical Journal of Dr. D.Y. Patil Vidyapeeth
In the field of antipsychotic medicines, clozapine and olanzapine are both structurally and functionally similar. This case study describes a 35-year-old man with paranoid schizophrenia who experienced a rare case of olanzapine-induced pancytopenia.
A Prajnashree, S. K Someshwar, Arfa A Sayed, K P Abhirami, Sanatkumar B. Nyamagoud   +4 more
doaj   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, Volume 183, Issue 7, Page 1364-1389, April 2026.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Olanzapine-induced Priapism in a Child with Asperger’s Syndrome

Balkan Medical Journal, 2017
Background: Priapism is a potentially painful and prolonged erection that occurs in the absence of any stimulation. Olanzapine has been reported to induce priapism in several adult cases with schizophrenia and/or mood disorders but very rarely reported ...
Hasan Bozkurt, Serkan Şahin
doaj   +1 more source

Avoidant‐Restrictive Food Intake Disorder in Patients With Gastrointestinal Disorders: A Systematic Review

Journal of Human Nutrition and Dietetics, Volume 39, Issue 2, April 2026.
ABSTRACT Introduction Avoidant‐restrictive food intake disorder (ARFID) is an eating disorder diagnosis implemented with DSM‐5 in 2013. Elevated risk for ARFID in patients with gastrointestinal disorders is suggested. This systematic review explored (1) methods used to identify patients with gastrointestinal disorders and comorbid ARFID and (2) their ...
Sissel Bekker Henriksen, Christina Hornemann, Ditte Roth Hulgaard   +2 more
wiley   +1 more source

Antipsychotic Use Among Intellectually Disabled Individuals With Rare Genetic Variants That Confer Risk for Schizophrenia

Journal of Intellectual Disability Research, Volume 70, Issue 4, Page 440-445, April 2026.
ABSTRACT Background Rare genetic variation can predispose individuals to the development of schizophrenia, with certain genes and copy number variants (CNVs) conferring risk at the exome/genome‐wide level. Despite this strong association, little is known about antipsychotic effectiveness and tolerability among individuals with most of these disorders ...
Mark Ainsley Colijn
wiley   +1 more source

Olanzapine: Are Extrapyramidal Symptoms as Rare as We Think? – A Case Series

Archives of Medicine and Health Sciences
Olanzapine, a second-generation antipsychotic has proven to be very efficacious with a low probability of extrapyramidal symptoms (EPS). Here, we wish to report a series of cases where EPS is occurring as a rare side effect due to olanzapine.
Akansha Bhardwaj, Bushra Zahoor, Kirti Yadav, Gunjan Chadha   +3 more
doaj   +1 more source

Olanzapine discontinuation emergent recurrence in bipolar disorder

Indian Journal of Psychological Medicine, 2014
Objective: The efficacy of atypical antipsychotics including olanzapine in acute treatment of manic episode has been established, whereas its role in maintenance treatment is not clear.
Manu Arora, Samir Kumar Praharaj
doaj   +1 more source

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment

British Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 869-878, March 2026.
Aims To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week.
Thomas Soeiro, Clémence Lacroix, Élisabeth Jouve, Élisabeth Frauger, Maryse Lapeyre‐Mestre, Joëlle Micallef   +5 more
wiley   +1 more source

Effects of risperidone and olanzapine on remnant-like lipoprotein particle cholesterol (RLP-C) in schizophrenic patients

Neuropsychiatric Disease and Treatment, 2008
Takahiko NagamineDivision of Psychiatric Internal Medicine, Seiwakai-Kitsunan Hospital, Suzenji, JapanAbstract: Second generation antipsychotics are associated with the risk of metabolic disorders such as diabetes mellitus and hyperlipidemia.
Takahiko Nagamine
doaj